Abbvie Inc
NYSE: ABBV
$211.77
+$0.22 (+0.1%)
Closing Price on March 14, 2025
ABBV Articles
ThinkstockThe short interest data have been released for the July 15 settlement date. Pharmaceutical companies are usually involved in a lengthy process in getting their drug candidates to market...
Published:
Last Updated:
AbbVie reported better-than-expected second-quarter financial results Friday before the markets opened.
Published:
Abbvie is scheduled to report its second-quarter financial results before the markets open Friday.
Published:
Earnings season is hitting its stride next week, and the health care sector, the biotech stocks in particular, have been on a roll for the past 12 months.
Published:
Last Updated:
A new report from Jefferies updates the firm's top global pharmaceutical stocks to buy, and these picks make sense for investors now.
Published:
The June 30 short interest data have been compared with the previous figures, and across the selected pharmaceutical stocks, short interest decreased.
Published:
A new report from UBS highlights three stocks that the firm likes best now. Not only do they all pay a solid dividend and have a good potential for growth, they all could help cushion a portfolio...
Published:
How much are big pharmaceutical companies really spending to get their drugs out there in the public eye?
Published:
The June 15 short interest data have been compared with the previous figures, and for the selected pharmaceutical stocks, short interest is mixed.
Published:
We screened the Jefferies Franchise Pick List for top stocks rated Buy with the highest upside to the Jefferies price targets.
Published:
The May 29 short interest data have been compared with the previous figures, and for most of the selected pharmaceutical stocks, short interest is down.
Published:
AT&T continued to reign as the most shorted stock trading on the New York Stock Exchange between the May 15 and May 29 settlement dates.
Published:
Credit Suisse has updated its autoimmune market model and it sees implications for all of the large cap U.S. pharmaceutical companies in its coverage.
Published:
Halozyme Therapeutics has announced a global collaboration and license agreement with AbbVie.
Published:
ThinkstockThe American Society of Clinical Oncology’s (ASCO) annual meeting is coming to a close. Companies and cancer drug developers across the health care sector flock to this conference to...
Published:
Our expert who first called NVIDIA in 2009 is predicting 2025 will see a historic AI breakthrough.
You can follow him investing $500,000 of his own money on our top AI stocks for free.